Holen Sie sich die Stockscreener-App
0.267
54.20%
-0.316
Handel nachbörslich:
.27
0.003
+1.12%
Schlusskurs vom Vortag:
$0.583
Offen:
$0.27375
24-Stunden-Volumen:
16.37M
Relative Volume:
28.09
Marktkapitalisierung:
$9.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.77M
KGV:
-0.0175
EPS:
-15.2954
Netto-Cashflow:
$-24.23M
1W Leistung:
-58.41%
1M Leistung:
-72.75%
6M Leistung:
-84.01%
1J Leistung:
-92.94%
1-Tages-Spanne:
$0.25
$0.3431
1-Wochen-Bereich:
$0.25
$0.7262
52-Wochen-Spanne:
$0.25
$4.707
Moleculin Biotech Inc Stock (MBRX) Company Profile
Firmenname
Moleculin Biotech Inc
Sektor
Branche
Telefon
713-300-5160
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Vergleichen Sie MBRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.267 | 9.35M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
Moleculin Biotech (MBRX) Rating Reiterated with $4.00 Price Target | MBRX Stock News - GuruFocus
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan - GuruFocus
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML - GlobeNewswire
Moleculin Participates in Virtual Investor “What This Means” Seg - GuruFocus
Moleculin Biotech’s Annamycin Pediatric Study Approved by FDA - TipRanks
Moleculin Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Moleculin Biotech (MBRX) Advances Pediatric Cancer Treatment Study | MBRX Stock News - GuruFocus
Moleculin Receives Critical FDA Support for Children's Leukemia Treatment Development - Stock Titan
Moleculin Biotech, Inc. Advances Annamycin for Pediatric Cancer Treatment as FDA Approves Inclusion of Younger Patients in Clinical Study - Nasdaq
FDA agrees to Moleculin’s pediatric study plan for cancer drug - Investing.com
Moleculin Biotech announces ‘What This Means’ virtual investor segment - Yahoo Finance
What is HC Wainwright’s Estimate for MBRX Q2 Earnings? - Defense World
Moleculin Biotech (MBRX) Reports Positive Results from Annamycin Trial | MBRX Stock News - GuruFocus
Moleculin Participates in Virtual Investor “What This Means” Segment | MBRX Stock News - GuruFocus
Moleculin Biotech, Inc. Reports Positive Topline Results from Phase 1B/2 Trial of Annamycin for Soft Tissue Sarcoma Lung Metastases - Nasdaq
Research Analysts Offer Predictions for MBRX Q4 Earnings - Defense World
Moleculin Biotech (NASDAQ:MBRX) Stock Rating Upgraded by HC Wainwright - Defense World
Moleculin Biotech (MBRX) Receives "Buy" Rating and $4.00 Price Target | MBRX Stock News - GuruFocus
Moleculin Biotech Reports Positive Annamycin Trial Results - MSN
Moleculin Biotech (MBRX) Receives Buy Rating and $4 Price Target | MBRX Stock News - GuruFocus
Moleculin Biotech Stock (MBRX) Dives 10% on Clinical Trial Results - The Globe and Mail
Moleculin Releases On-Demand KOL Webcast to Discuss Data - GlobeNewswire
Transcript : Moleculin Biotech, Inc.Pre Recorded Shareholder/Analyst Call - MarketScreener
Moleculin Biotech, Inc. Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - MarketScreener
Moleculin Biotech Hosts Key Opinion Leaders Event - TipRanks
Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Moleculin Biotech (MBRX) Presents Final Data from Annamycin Clin - GuruFocus
Leading Oncologists Review Breakthrough Data from Moleculin's Sarcoma Lung Metastases Trial - Stock Titan
Moleculin announces efficacy results from trial of Annamycin for STS lung mets - Yahoo Finance
Moleculin Reports Positive Topline Efficacy Results from U.S. Ph - GuruFocus
Moleculin Biotech Shares Slump After Phase 1b/2 Trial of Annamycin Fails to Show Complete Responses - MarketScreener
Moleculin Biotech (MBRX) Reports Promising Phase 1B/2 Trial Resu - GuruFocus
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) | MBRX Stock News - GuruFocus
Moleculin Biotech Reports Promising Efficacy Results for Annamycin in Phase 1B/2 Trial for Soft Tissue Sarcoma Lung Metastases - Nasdaq
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - GlobeNewswire
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - GlobeNewswire Inc.
Breakthrough: Moleculin's Cancer Drug Achieves 59.4% Clinical Benefit Rate in Late-Stage Trial - Stock Titan
Roth Capital Partners Manages New Developments for Moleculin Biotech (MBRX) | MBRX Stock News - GuruFocus
Roth Capital Partners Manages New Developments for Moleculin Bio - GuruFocus
Moleculin receives Nasdaq non-compliance notice By Investing.com - Investing.com South Africa
Moleculin Biotech Faces Nasdaq Non-Compliance Notice - TipRanks
Moleculin receives Nasdaq non-compliance notice - Investing.com
Moleculin signals first 45-patient unblinding for Phase 3 AML trial by end of 2025 as key regulatory milestones achieved - MSN
Q2 EPS Forecast for Moleculin Biotech Increased by Analyst - Defense World
Moleculin Biotech reaches agreement to amend investor warrants - MSN
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Announces First European Approval for Phase 3 AML Trial - MSN
Moleculin Biotech’s Earnings Call: Trials and Triumphs - TipRanks
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: S - GuruFocus
Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.86%
1.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):